Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2023-02-14 3:14 pm Sale |
2022-12-31 | 13G | Constellation Pharmaceuticals, Inc. CNST |
Cormorant Asset Management LP | 5,150,000 9.210% |
-290,451 (-5.34%) |
Filing History |
| 2023-02-14 3:13 pm Sale |
2022-12-31 | 13G | GreenLight Biosciences Holdings GRNA |
Cormorant Asset Management LP | 9,188,659 6.060% |
-290,399 (-3.06%) |
Filing History |
| 2023-02-14 3:13 pm Purchase |
2022-12-31 | 13G | Immuneering Corporation IMRX |
Cormorant Asset Management LP | 2,286,181 8.660% |
33,553 (+1.49%) |
Filing History |
| 2023-02-14 3:12 pm Sale |
2022-12-31 | 13G | Ambrx Biopharma Inc. AMAM |
Cormorant Asset Management LP | 16,354,702 6.050% |
-911,442 (-5.28%) |
Filing History |
| 2023-02-14 3:11 pm Sale |
2022-12-31 | 13G | Monte Rosa Therapeutics, Inc. GLUE |
Cormorant Asset Management LP | 2,893,717 5.980% |
-108,483 (-3.61%) |
Filing History |
| 2023-02-14 3:10 pm Purchase |
2022-12-31 | 13G | BioAtla, Inc. BCAB |
Cormorant Asset Management LP | 3,680,365 7.980% |
1,642,150 (+80.57%) |
Filing History |
| 2023-02-14 3:10 pm Purchase |
2022-12-31 | 13G | Aerovate Therapeutics, Inc. AVTE |
Cormorant Asset Management LP | 55,918 7.950% |
3,613 (+6.91%) |
Filing History |
| 2023-02-14 3:09 pm Sale |
2022-12-31 | 13G | Cabaletta Bio, Inc. CABA |
Cormorant Asset Management LP | 1,971,739 6.770% |
-28,261 (-1.41%) |
Filing History |
| 2023-02-14 3:08 pm Sale |
2022-12-31 | 13G | Arcellx, Inc. ACLX |
Cormorant Asset Management LP | 2,075,000 4.730% |
-125,000 (-5.68%) |
Filing History |
| 2023-02-14 3:08 pm Sale |
2022-12-31 | 13G | Olema Pharmaceuticals, Inc. OLMA |
Cormorant Asset Management LP | 2,082,000 5.150% |
-87,871 (-4.05%) |
Filing History |
| 2023-02-14 3:07 pm Sale |
2022-12-31 | 13G | Altimmune, Inc. ALT |
Cormorant Asset Management LP | 2,600,000 5.290% |
-400,000 (-13.33%) |
Filing History |
| 2023-02-14 3:05 pm Sale |
2022-12-31 | 13G | Viridian Therapeutics, Inc. VRDN |
Cormorant Asset Management LP | 1,100,000 2.730% |
-336,322 (-23.42%) |
Filing History |
| 2023-02-14 3:05 pm Purchase |
2022-12-31 | 13G | Longboard Pharmaceuticals, Inc. LBPH |
Cormorant Asset Management LP | 1,801,947 9.990% |
420,015 (+30.39%) |
Filing History |
| 2023-02-14 3:04 pm Purchase |
2022-12-31 | 13G | Tarsus Pharmaceuticals, Inc. TARS |
Cormorant Asset Management LP | 1,736,422 6.510% |
333,091 (+23.74%) |
Filing History |
| 2023-02-14 3:03 pm Purchase |
2022-12-31 | 13G | Astria Therapeutics, Inc. ATXS |
Cormorant Asset Management LP | 1,650,000 6.300% |
450,000 (+37.50%) |
Filing History |
| 2023-02-14 3:03 pm Sale |
2022-12-31 | 13G | VectivBio Holding AG VECT |
Cormorant Asset Management LP | 2,536,617 4.040% |
-303,772 (-10.69%) |
Filing History |
| 2023-02-14 3:02 pm Sale |
2022-12-31 | 13G | Tango Therapeutics, Inc. TNGX |
Cormorant Asset Management LP | 4,116,949 4.670% |
-782,235 (-15.97%) |
Filing History |
| 2023-02-14 3:01 pm Sale |
2022-12-31 | 13G | Prometheus Biosciences, Inc. RXDX |
Cormorant Asset Management LP | 2,090,000 4.500% |
-134,847 (-6.06%) |
Filing |
| 2023-02-14 3:00 pm Sale |
2022-12-31 | 13G | Eledon Pharmaceuticals, Inc. ELDN |
Cormorant Asset Management LP | 1,391,663 9.990% |
-36,935 (-2.59%) |
Filing History |
| 2022-12-29 4:15 pm Purchase |
2022-12-19 | 13G | 89bio, Inc. ETNB |
Cormorant Asset Management LP | 2,550,000 5.480% |
2,550,000 (New Position) |
Filing History |